Update on tumor neoantigens and their utility: Why it is good to be different Journal Article


Authors: Lee, C. H.; Yelensky, R.; Jooss, K.; Chan, T. A.
Article Title: Update on tumor neoantigens and their utility: Why it is good to be different
Abstract: Antitumor rejection by the immune system is a complex process that is regulated by several factors. Among these factors are the quality and quantity of mutational events that occur in cancer cells. Perhaps one of the most important types of mutations that influence antitumor immunity is the neoantigen, that is, a non-self-antigen that arises as a result of somatic mutation. Recent work has demonstrated that neoantigens hold significant promise for developing new diagnostic and therapeutic modalities. Therapeutic targeting of neoantigens is important for achieving benefit following therapy with immune checkpoint blockade agents or for cancer vaccines targeting mutations. Here, we review our understanding of neoantigens and discuss new developments in the quest to use them in cancer immunotherapy. © 2018 Elsevier Ltd
Journal Title: Trends in Immunology
Volume: 39
Issue: 7
ISSN: 1471-4906
Publisher: Elsevier Inc.  
Date Published: 2018-07-01
Start Page: 536
End Page: 548
Language: English
DOI: 10.1016/j.it.2018.04.005
PROVIDER: scopus
PUBMED: 29751996
PMCID: PMC7954132
DOI/URL:
Notes: Review -- Export Date: 2 July 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Timothy Chan
    317 Chan
  2. Chung-Han   Lee
    157 Lee